BioCentury
ARTICLE | Financial News

ContraVir seeking public listing

August 9, 2013 11:35 PM UTC

The ContraVir Pharmaceuticals Inc. subsidiary of gastrointestinal company Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) filed a Form 10 with the SEC to become a publicly reporting company listed on the OTC Bulletin Board. Synergy created the subsidiary in May to house shingles product FV-100, which Synergy acquired from Bristol-Myers Squibb Co. (NYSE:BMY) last year for $1 million up front and an undisclosed amount in milestones, plus royalties. BMS had acquired the oral bicyclic nucleoside analog, which has completed a Phase IIa trial to treat Varicella zoster virus (VZV) infection (shingles), through its $2.5 billion takeover of Inhibitex Inc. Synergy shareholders will also own ContraVir (see BioCentury Extra, Aug. 23, 2012). ...